SEK110 0.0 0.0%
Last Trade - 26/02/21
| Market Cap | ÂŁ105.1m |
| Enterprise Value | ÂŁ69.1m |
| Revenue | ÂŁn/a |
| Position in Universe | 876th / 1874 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.16 | 0.24 | 0.000 | 0.000 | 0.000 | 133.7 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Public Since | March 29, 2016 |
| No. of Shareholders: | n/a |
| No. of Employees: | 9 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | OMX Nordic Exchange Stockholm |
| Shares in Issue | 11,226,184 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Bryggargatan 10, STOCKHOLM, 111 21, Sweden |
| Web | http://ibtherapeutics.com/ |
| Phone | +46 8 41014555 |
| Contact | Staffan Stromberg (Chief Executive Officer) |
| Auditors | Deloitte AB |
As of 26/02/21, shares in Infant Bacterial Therapeutics AB are trading at SEK110, giving the company a market capitalisation of ÂŁ105.1m. This share price information is delayed by 15 minutes.
Shares in Infant Bacterial Therapeutics AB are currently trading at SEK110 and the price has moved by -12.84% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Infant Bacterial Therapeutics AB price has moved by -19.49% over the past year.
Of the analysts with advisory recommendations for Infant Bacterial Therapeutics AB, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Infant Bacterial Therapeutics AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Infant Bacterial Therapeutics AB is scheduled to issue upcoming financial results on the following dates:
Infant Bacterial Therapeutics AB does not currently pay a dividend.
Infant Bacterial Therapeutics AB does not currently pay a dividend.
Infant Bacterial Therapeutics AB does not currently pay a dividend.
To buy shares in Infant Bacterial Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Infant Bacterial Therapeutics AB are currently trading at SEK110, giving the company a market capitalisation of ÂŁ105.1m.
Here are the trading details for Infant Bacterial Therapeutics AB:
Based on an overall assessment of its quality, value and momentum, Infant Bacterial Therapeutics AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Infant Bacterial Therapeutics AB are currently priced at SEK110. At that level they are trading at 0.264% discount to the analyst consensus target price of 0.00.
Analysts covering Infant Bacterial Therapeutics AB currently have a consensus Earnings Per Share (EPS) forecast of -15.62 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Infant Bacterial Therapeutics AB. Over the past six months, the relative strength of its shares against the market has been -46.76%. At the current price of SEK110, shares in Infant Bacterial Therapeutics AB are trading at -16.9% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Infant Bacterial Therapeutics AB.
Infant Bacterial Therapeutics AB's management team is headed by:
Here are the top five shareholders of Infant Bacterial Therapeutics AB based on the size of their shareholding:
